Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo Over 52 Weeks in Patients With Moderate to Severe Persistent Asthma
Brief Summary: The aim of this trial is to evaluate the safety and efficacy of 2.5 and 5 µg tiotropium over a 52-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat inhaler will be examined on top of maintenance treatment with inhaled corticosteroid controller medication in patients with moderate to severe persistent asthma. Efficacy and safety will be assessed by measuring effects on lung function, effects on asthma exacerbations, effects on asthma control, and number of adverse events.


Options:
A: Arm Label: Tiotropium Respimat (low dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Tiotropium Respimat (high dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Placebo Respimat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (high dose) | Intervention Type: DRUG; Name: Placebo Respimat; Assigned to Arm(s): Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (low dose)
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Arm Label: UMEC 62.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Arm Label: UMEC 31.25 mcg; Type: EXPERIMENTAL; Interventions: Drug: UMEC, Drug: Fluticasone Furoate, Drug: Albuterol/salbutamol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: UMEC; Assigned to Arm(s): UMEC 31.25 mcg, UMEC 62.5 mcg | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): Placebo, UMEC 31.25 mcg, UMEC 62.5 mcg | Intervention Type: DRUG; Name: Albuterol/salbutamol; Assigned to Arm(s): Placebo, UMEC 31.25 mcg, UMEC 62.5 mcg
C: Arm Label: Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Tiotropium | Arm Label: Salmeterol or Formoterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Formoterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol or Formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Salmeterol or Formoterol
D: Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: tiotropium Respimat® low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: tiotropium Respimat® high dose | Arm Label: 50 mcg salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mcg salmeterol HFA MDI, Drug: Placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: tiotropium Respimat® low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): tiotropium high dose | Intervention Type: DRUG; Name: tiotropium Respimat® high dose; Assigned to Arm(s): tiotropium high dose | Intervention Type: DRUG; Name: 50 mcg salmeterol HFA MDI; Assigned to Arm(s): 50 mcg salmeterol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 50 mcg salmeterol

Answer: A